SK182004A3 - Freeze-dried composition containing olanzapine - Google Patents

Freeze-dried composition containing olanzapine Download PDF

Info

Publication number
SK182004A3
SK182004A3 SK18-2004A SK182004A SK182004A3 SK 182004 A3 SK182004 A3 SK 182004A3 SK 182004 A SK182004 A SK 182004A SK 182004 A3 SK182004 A3 SK 182004A3
Authority
SK
Slovakia
Prior art keywords
olanzapine
composition
disorders
agitation
stabilizer
Prior art date
Application number
SK18-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Kurt Douglas Dekemper
Alan Lee Fites
Steven L Nail
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SK182004A3 publication Critical patent/SK182004A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SK18-2004A 2001-07-20 2002-07-05 Freeze-dried composition containing olanzapine SK182004A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30682901P 2001-07-20 2001-07-20
US38647402P 2002-06-07 2002-06-07
PCT/US2002/019799 WO2003007912A2 (en) 2001-07-20 2002-07-05 Lyophilized formulation comprising olanzapine

Publications (1)

Publication Number Publication Date
SK182004A3 true SK182004A3 (en) 2004-09-08

Family

ID=26975390

Family Applications (1)

Application Number Title Priority Date Filing Date
SK18-2004A SK182004A3 (en) 2001-07-20 2002-07-05 Freeze-dried composition containing olanzapine

Country Status (33)

Country Link
US (1) US20040176357A1 (hr)
EP (1) EP1423124B1 (hr)
JP (1) JP2004537546A (hr)
KR (1) KR20040017330A (hr)
CN (1) CN1537007A (hr)
AR (1) AR036180A1 (hr)
AT (1) ATE369137T1 (hr)
AU (1) AU2002320134B2 (hr)
BR (1) BR0211250A (hr)
CA (1) CA2448724A1 (hr)
CO (1) CO5540279A2 (hr)
CY (1) CY1107759T1 (hr)
CZ (1) CZ200484A3 (hr)
DE (1) DE60221674T2 (hr)
DK (1) DK1423124T3 (hr)
EA (1) EA006506B1 (hr)
ES (1) ES2289126T3 (hr)
HK (1) HK1066484A1 (hr)
HR (1) HRP20040037A2 (hr)
HU (1) HUP0401157A3 (hr)
IL (1) IL159098A0 (hr)
MX (1) MXPA04000541A (hr)
MY (1) MY135452A (hr)
NZ (1) NZ529667A (hr)
PE (1) PE20030281A1 (hr)
PL (1) PL366614A1 (hr)
PT (1) PT1423124E (hr)
SI (1) SI1423124T1 (hr)
SK (1) SK182004A3 (hr)
SV (1) SV2003001179A (hr)
UA (1) UA80095C2 (hr)
WO (1) WO2003007912A2 (hr)
ZA (1) ZA200400798B (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003300324A1 (en) * 2002-12-24 2004-07-22 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
HU226410B1 (en) * 2003-04-22 2008-11-28 Egis Gyogyszergyar Nyilvanosan Novel polymorphous forms of olanzapine hydrochlorides, process for producing them, use thereof and pharmaceutical compositions containing them
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
AR047459A1 (es) 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
WO2006076124A2 (en) * 2004-12-16 2006-07-20 Nektar Therapeutics Stable, non-crystalline formulation comprising olanzapine
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007134845A2 (en) * 2006-05-18 2007-11-29 Synthon B.V. Olanzapine pharmaceutical composition
BR112020013750A8 (pt) * 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
CN115006406A (zh) * 2021-12-28 2022-09-06 南京清普生物科技有限公司 一种稳定的奥氮平制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2059947T3 (es) * 1989-09-30 1994-11-16 Eisai Co Ltd Preparados inyectables que contienen cefalosporina y utilizacion de los mismos.
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use

Also Published As

Publication number Publication date
ATE369137T1 (de) 2007-08-15
ZA200400798B (en) 2005-07-27
HUP0401157A2 (hu) 2004-10-28
CA2448724A1 (en) 2003-01-30
IL159098A0 (en) 2004-05-12
PL366614A1 (en) 2005-02-07
PT1423124E (pt) 2007-10-29
CN1537007A (zh) 2004-10-13
WO2003007912A3 (en) 2003-05-01
CY1107759T1 (el) 2013-06-19
UA80095C2 (en) 2007-08-27
DE60221674T2 (de) 2008-04-30
WO2003007912A2 (en) 2003-01-30
EA006506B1 (ru) 2005-12-29
US20040176357A1 (en) 2004-09-09
DK1423124T3 (da) 2007-12-03
KR20040017330A (ko) 2004-02-26
NZ529667A (en) 2006-02-24
AR036180A1 (es) 2004-08-18
ES2289126T3 (es) 2008-02-01
EP1423124B1 (en) 2007-08-08
JP2004537546A (ja) 2004-12-16
EP1423124A2 (en) 2004-06-02
DE60221674D1 (de) 2007-09-20
MY135452A (en) 2008-04-30
SV2003001179A (es) 2003-07-29
BR0211250A (pt) 2004-07-27
EA200400211A1 (ru) 2004-06-24
CZ200484A3 (cs) 2005-01-12
PE20030281A1 (es) 2003-03-27
HUP0401157A3 (en) 2008-01-28
CO5540279A2 (es) 2005-07-29
HK1066484A1 (en) 2005-03-24
HRP20040037A2 (en) 2004-06-30
MXPA04000541A (es) 2004-05-04
AU2002320134B2 (en) 2007-04-05
SI1423124T1 (sl) 2008-02-29

Similar Documents

Publication Publication Date Title
JP5406197B2 (ja) ダントロレン治療剤の送達を改善するための、共溶媒組成物および方法
RU2221563C2 (ru) Фармацевтическая композиция для лечения болезни паркинсона и синдромов паркинсона, способ ее получения, способ лечения болезни паркинсона и синдромов паркинсона
US20090176855A1 (en) Treatment of bipolar disorders and associated symptoms
EP2891494B1 (en) Method for administering hypnotic/sedative agent
US5629312A (en) Use of lamotrigine for treating AIDS-related neural disorders
KR20030069995A (ko) 약제학적 조성물
JP6182262B2 (ja) 抗がん剤を含む安定な水溶性医薬組成物
SK182004A3 (en) Freeze-dried composition containing olanzapine
BR112012002265B1 (pt) composições farmacêuticas para o tratamento de câncer e outras doenças ou distúrbios
EA004539B1 (ru) Комбинационная терапия для лечения резистентной депрессии
AU2002320134A1 (en) Lyophilized formulation comprising olanzapine
US20160235717A1 (en) Bendamustine pharmaceutical compositions
TW522015B (en) Pharmaceutical compositions for freeze drying
CN102666510B (zh) 基本上纯净的亚甲蓝五水合物形式a的制备方法及其用途
CN108350457B (zh) 稳定地含有抑制TGF-β1基因的表达的单链核酸分子的组合物
WO2003084542A1 (fr) Accelerateur de production d'un facteur neurotrophique
CN102429903A (zh) 供注射用奥扎格雷钠药物组合物
EP0733368A1 (en) Granule fomulation for olanzapine
RU2192855C1 (ru) Способ получения лекарственного средства для инъекций на основе амиодарона
EP3888636A2 (en) Donepezil eutectic mixture and use thereof
EA044843B1 (ru) Кристаллическая форма ингибитора plk4
EP4316493A1 (en) Novel use of cyclic ketone compound
EA002676B1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка